Total Payments
$118,921
2024 Payments
$23,664
Companies
32
Transactions
390
Medicare Patients
826
Medicare Billing
$88,200
Payment Breakdown by Category
Other$89,172 (75.0%)
Consulting$17,495 (14.7%)
Food & Beverage$7,815 (6.6%)
Travel$4,307 (3.6%)
Education$131.45 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $89,172 | 34 | 75.0% |
| Consulting Fee | $17,495 | 5 | 14.7% |
| Food and Beverage | $7,815 | 307 | 6.6% |
| Travel and Lodging | $4,307 | 39 | 3.6% |
| Education | $131.45 | 5 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $113,822 | 119 | $0 (2024) |
| ViiV Healthcare Company | $1,140 | 76 | $0 (2024) |
| Gilead Sciences, Inc. | $1,127 | 59 | $0 (2024) |
| Janssen Biotech, Inc. | $472.01 | 32 | $0 (2021) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $468.25 | 9 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $289.67 | 7 | $0 (2021) |
| ABBVIE INC. | $276.75 | 8 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $244.53 | 22 | $0 (2023) |
| Janssen Products, LP | $184.84 | 3 | $0 (2020) |
| Allergan, Inc. | $121.72 | 4 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,664 | 29 | Novo Nordisk Inc ($23,572) |
| 2023 | $26,785 | 28 | Novo Nordisk Inc ($26,770) |
| 2022 | $36,597 | 38 | Novo Nordisk Inc ($36,597) |
| 2021 | $27,084 | 36 | Novo Nordisk Inc ($26,798) |
| 2020 | $860.49 | 53 | ViiV Healthcare Company ($211.87) |
| 2019 | $1,026 | 57 | ViiV Healthcare Company ($312.84) |
| 2018 | $1,623 | 98 | ViiV Healthcare Company ($369.25) |
| 2017 | $1,281 | 51 | Gilead Sciences Inc ($374.51) |
All Payment Transactions
390 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $25.04 | General |
| Category: HIV | ||||||
| 12/16/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $24.68 | General |
| Category: HIV | ||||||
| 12/04/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Obesity | ||||||
| 11/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.23 | General |
| 11/07/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,843.75 | General |
| Category: Obesity | ||||||
| 11/07/2024 | Novo Nordisk Inc | Wegovy (Drug) | Travel and Lodging | In-kind items and services | $261.30 | General |
| Category: Obesity | ||||||
| 11/07/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $84.93 | General |
| Category: Obesity | ||||||
| 11/07/2024 | Novo Nordisk Inc | Wegovy (Drug) | Travel and Lodging | In-kind items and services | $3.90 | General |
| Category: Obesity | ||||||
| 10/28/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Obesity | ||||||
| 10/28/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: Obesity | ||||||
| 10/28/2024 | ABBVIE INC. | AVYCAZ (Drug), DALVANCE, TEFLARO | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/04/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Obesity | ||||||
| 10/02/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,093.75 | General |
| Category: Obesity | ||||||
| 10/02/2024 | Novo Nordisk Inc | Wegovy (Drug) | Travel and Lodging | In-kind items and services | $168.84 | General |
| Category: Obesity | ||||||
| 10/02/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $122.83 | General |
| Category: Obesity | ||||||
| 10/02/2024 | Novo Nordisk Inc | Wegovy (Drug) | Travel and Lodging | In-kind items and services | $8.70 | General |
| Category: Obesity | ||||||
| 09/18/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,281.25 | General |
| Category: Obesity | ||||||
| 09/18/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $2,625.00 | General |
| 09/18/2024 | Novo Nordisk Inc | Wegovy (Drug) | Travel and Lodging | In-kind items and services | $99.16 | General |
| Category: Obesity | ||||||
| 09/18/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $32.31 | General |
| Category: Obesity | ||||||
| 09/18/2024 | Novo Nordisk Inc | Wegovy (Drug) | Travel and Lodging | In-kind items and services | $4.25 | General |
| Category: Obesity | ||||||
| 07/15/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $159.50 | General |
| Category: Obesity | ||||||
| 06/18/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $18.73 | General |
| 05/31/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,042.25 | General |
| Category: Obesity | ||||||
| 05/31/2024 | Novo Nordisk Inc | Wegovy (Drug) | Travel and Lodging | In-kind items and services | $439.96 | General |
| Category: Obesity | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 6 | 193 | 242 | $36,452 | $14,289 |
| 2020 | 19 | 633 | 2,368 | $175,573 | $73,911 |
Total Patients
826
Total Services
2,610
Medicare Billing
$88,200
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 74 | 95 | $12,919 | $5,166 | 40.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 51 | 65 | $12,793 | $4,848 | 37.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 22 | 29 | $5,386 | $2,162 | 40.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 16 | 22 | $2,834 | $1,240 | 43.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 19 | 19 | $2,451 | $834.68 | 34.1% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2021 | 11 | 12 | $68.88 | $38.86 | 56.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 19 | 1,501 | $54,016 | $22,705 | 42.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 140 | 251 | $47,740 | $18,824 | 39.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 120 | 177 | $23,141 | $8,725 | 37.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 53 | 81 | $15,081 | $6,572 | 43.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 26 | 27 | $9,758 | $4,184 | 42.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 37 | 57 | $7,364 | $3,265 | 44.3% |
| 99495 | Transitional care management services, moderately complexity, requiring face-to-face visits within 14 days of discharge | Office | 2020 | 14 | 15 | $4,832 | $2,132 | 44.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 16 | 16 | $3,224 | $1,774 | 55.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 22 | 22 | $2,853 | $1,266 | 44.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 19 | 23 | $1,125 | $907.17 | 80.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 12 | 12 | $865.80 | $700.77 | 80.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 35 | 36 | $1,269 | $567.12 | 44.7% |
| 90674 | Vaccine for influenza for administration into muscle, 0.5 ml dosage | Office | 2020 | 20 | 20 | $845.32 | $555.38 | 65.7% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 16 | 25 | $625.75 | $442.70 | 70.7% |
| 90756 | Vaccine for influenza for injection into muscle | Office | 2020 | 13 | 14 | $647.52 | $383.09 | 59.2% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 25 | 35 | $864.50 | $380.52 | 44.0% |
| 99211 | Established patient office or other outpatient visit, typically 5 minutes | Office | 2020 | 15 | 18 | $711.90 | $243.74 | 34.2% |
| G0009 | Administration of pneumococcal vaccine | Office | 2020 | 12 | 13 | $458.12 | $202.58 | 44.2% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2020 | 19 | 25 | $151.75 | $81.16 | 53.5% |
About Dr. Stacy Chronister, D.O
Dr. Stacy Chronister, D.O is a Internal Medicine healthcare provider based in Tulsa, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/25/2008. The National Provider Identifier (NPI) number assigned to this provider is 1194987750.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stacy Chronister, D.O has received a total of $118,921 in payments from pharmaceutical and medical device companies, with $23,664 received in 2024. These payments were reported across 390 transactions from 32 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($89,172).
As a Medicare-enrolled provider, Chronister has provided services to 826 Medicare beneficiaries, totaling 2,610 services with total Medicare billing of $88,200. Data is available for 2 years (2020–2021), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Obesity Medicine, Internal Medicine
- Location Tulsa, OK
- Active Since 06/25/2008
- Last Updated 10/21/2019
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1194987750
Products in Payments
- Wegovy (Drug) $58,116
- Saxenda (Drug) $37,675
- LifeVest (Device) $468.25
- DOVATO (Drug) $386.46
- PREZCOBIX (Drug) $302.47
- TRIUMEQ (Drug) $291.69
- JULUCA (Drug) $263.91
- ENTRESTO (Drug) $229.70
- Mavyret (Drug) $210.59
- SYMTUZA (Drug) $201.92
- BREZTRI AEROSPHERE (Drug) $137.25
- Symtuza (Drug) $112.27
- BREZTRI (Drug) $109.75
- DALVANCE (Drug) $85.18
- Biktarvy (Drug) $71.47
- JARDIANCE (Drug) $62.27
- ISENTRESS (Drug) $61.33
- CABENUVA (Biological) $41.85
- FARXIGA (Drug) $39.87
- XIFAXAN (Drug) $39.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Tulsa
Dr. Anuj Malik, Md, MD
Internal Medicine — Payments: $559,128
Internal Medicine $559,128
Mousumi Som, Do, DO
Internal Medicine — Payments: $182,416
Internal Medicine $182,416
Madhuri Lad, D.o, D.O
Internal Medicine — Payments: $160,090
Internal Medicine $160,090
Jesse Richards, D.o, D.O
Internal Medicine — Payments: $147,415
Internal Medicine $147,415
Mr. Eugene Ichinose, M.d, M.D
Internal Medicine — Payments: $113,876
Internal Medicine $113,876
Dr. Hassan Abouhouli, Md, MD
Internal Medicine — Payments: $105,547
Internal Medicine $105,547